Credo, Cellebrite, and TransMedics are building dominant positions in huge markets with years of expansion still ahead.

TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.

The stock plunged, but its transplant platform may still be building a powerful moat. Is this a rare opportunity, or a margin ...

TransMedics Group remains a Strong Buy, driven by robust revenue growth, expanding organ platforms, and strategic international initiatives. TMDX’s Organ Care System leads transplant technology, with ...

TransMedics remains the top dog in its industry and may have a widening moat. The founder-led company's shares have risen eightfold since 2019. TransMedics is consistently considered "overvalued," but ...

TransMedics Group is a strong buy, leveraging its technological and logistical moat in organ transport, with OCS and NOP programs driving sector outperformance. TMDX trades at a 39x non-GAAP PE and ...

ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That's why investors should sometimes look toward ...

Storing organs for transplants isn't easy. The traditional cold storage method has significant drawbacks. Many (in some cases, most) organs that are kept and transported that way end up deteriorating ...